Literature DB >> 30367458

Preventative tracheal administration of interleukin-27 attenuates allergic asthma by improving the lung Th1 microenvironment.

Xiaojing Liu1,2, Shanqun Li1, Jianjun Jin3, Tao Zhu4, Kan Xu5, Cheng Liu6, Yuzhen Zeng1, Ruolin Mao1, Xiangdong Wang3, Zhihong Chen1.   

Abstract

BACKGROUND: Interleukin-27 (IL-27) modulates CD4+ T-cell differentiation and function. The aim of this study is to investigate the effect and molecular mechanisms of IL-27 on the development of asthma.
METHODS: IL-27 was intranasally administered in an ovalbumin-induced asthma model, and lung mononuclear cells and different Th cell classes were detected by fluorescence-activated cell sorting. The effect and mechanisms of IL-27 on human bronchial epithelial (HBE) cells were investigated by measuring changes in chemotactic factors, cytokines, transcription factors, and signaling pathways.
RESULTS: We found that intranasal administration of IL-27 could attenuate airway inflammation and hyperresponsiveness, upregulate the type 1 T helper (Th1)-T memory (Tm) cells and regulatory T (Treg) cells subgroups of lung tissue lymphocytes, and diminish the levels of type 2 T helper (Th2) cytokines. IL-27 upregulated the expression of C-C motif chemokine ligand 2 (CCL2), CCL3, and CCL4 in HBE cells and promoted the production of chemotactic factors to attract monocyte recruitment. Recruited monocytes secondarily secreted IL-27 to influence HBE cells in a positive feedback cycle. After IL-27 intervention, signal transducer and activator of transcription 1 (STAT1) phosphorylation increased, while STAT4 and STAT6 phosphorylation declined.
CONCLUSIONS: Preventative intranasal administration of IL-27 can recruit more IL-27-secreted monocytes to the airway and change the different T-cell classes in lung. The improved Th1 environment helps to alleviate Th2-mediated allergic asthma by repairing the STAT1 pathway but not the STAT4 pathway.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Th1 environment; asthma; interleukin-27

Mesh:

Substances:

Year:  2018        PMID: 30367458     DOI: 10.1002/jcp.27422

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  Resolution of allergic asthma.

Authors:  Susetta Finotto
Journal:  Semin Immunopathol       Date:  2019-11-08       Impact factor: 9.623

2.  IL‑27 suppresses airway inflammation, hyperresponsiveness and remodeling via the STAT1 and STAT3 pathways in mice with allergic asthma.

Authors:  Degan Lu; Jiameng Lu; Xiaoqing Ji; Yanbo Ji; Zewen Zhang; Haiying Peng; Fei Sun; Caiqing Zhang
Journal:  Int J Mol Med       Date:  2020-05-29       Impact factor: 4.101

3.  Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients.

Authors:  Maria Xydia; Raheleh Rahbari; Eliana Ruggiero; Iain Macaulay; Maxime Tarabichi; Robert Lohmayer; Stefan Wilkening; Tillmann Michels; Daniel Brown; Sebastiaan Vanuytven; Svetlana Mastitskaya; Sean Laidlaw; Niels Grabe; Maria Pritsch; Raffaele Fronza; Klaus Hexel; Steffen Schmitt; Michael Müller-Steinhardt; Niels Halama; Christoph Domschke; Manfred Schmidt; Christof von Kalle; Florian Schütz; Thierry Voet; Philipp Beckhove
Journal:  Nat Commun       Date:  2021-02-18       Impact factor: 14.919

Review 4.  Exploring the role of interleukin-27 as a regulator of neuronal survival in central nervous system diseases.

Authors:  Andrea N Nortey; Kimberly N Garces; Abigail S Hackam
Journal:  Neural Regen Res       Date:  2022-10       Impact factor: 6.058

5.  Interleukin‑27 ameliorates allergic asthma by alleviating the lung Th2 inflammatory environment.

Authors:  Jiameng Lu; Xiaoqing Ji; Lixia Wang; Fei Sun; Chuanjun Huang; Haiying Peng; Yunxiu Jiang; Zihan Guo; Xinyi Liu; Yanbo Ji; Degan Lu
Journal:  Int J Mol Med       Date:  2022-05-06       Impact factor: 5.314

Review 6.  Interleukin-27 Functional Duality Balances Leishmania Infectivity and Pathogenesis.

Authors:  Abdollah Jafarzadeh; Maryam Nemati; Prashant Chauhan; Ashok Patidar; Arup Sarkar; Iraj Sharifi; Bhaskar Saha
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.